For antibody drug conjugates to reach their full potential, developers should focus on addressing current challenges such as safety and efficacy.
Andreas Dreps
Advertisement
Senior VP and Global Head Drug Development Unit, ICON plc
Articles by Andreas Dreps
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
When There’s No Registry: Building Rare Disease Evidence That Supports Regulatory Scrutiny
2
How AI Is Changing Endpoint Selection Before a Trial Even Starts
3
The Design Flaws Trial Simulations Surface That Traditional Planning Misses
4
ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval
5